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Overexpression of glial cell line-derived neurotrophic factor
(GDNF) in embryonic muscle fibers causes dramatic hyperin-
nervation of neuromuscular junctions. However, it is not known
whether GDNF induces the extra innervation by regulation of
axonal branching and/or synaptic maintenance. To address this
issue, high levels of circulating GDNF were established by
administering subcutaneous injections starting either at birth or
later and continuing for up to 40 d. Treatment with exogenous
GDNF beginning in the first week, but not later, increased the
number of axons converging at neuromuscular junctions. The
effect of GDNF on the branching pattern of individual motor
axons was determined by reconstructing labeled axonal arbors
from transgenic mice expressing yellow fluorescent protein in
subsets of motor neurons. Whereas, at postnatal day 8 (P8)
individual axons in control animals branched to sporadically
innervate junctions within circumscribed regions of the muscle,
motor units from GDNF injected animals had significantly more
axonal branches and exhibited a high degree of localized ar-
borization such that adjacent muscle fibers were often inner-
vated by the same axon. Administration beginning at P0 and
continuing through P40 prolonged multiple innervation of most
fibers throughout the period of injection. Between P30 and P40
there was no net change in multiple innervation, although there
was evidence of retraction bulbs, suggesting that axon exten-
sion and retraction were in equilibrium. We conclude that GDNF
has a developmentally regulated effect on presynaptic branch-
ing and that sustained administration of GDNF induces a state
of continuous synaptic remodeling.
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A number of recent studies have demonstrated that neuronal
growth factors influence synapses in many parts of the nervous
system. For example, in autonomic ganglia, brain-derived neuro-
trophic factor (BDNF) has been shown to alter synaptic density,
suggesting that growth factor levels regulate synaptogenesis
(Causing et al., 1997). Activity-mediated synaptic rearrange-
ments in the CNS are also influenced by BDNF and NT-4/5
(Cabelli et al., 1995, 1997). At the neuromuscular junction
(NMJ), several trophic factors influence developmental synaptic
rearrangements (English and Schwartz, 1995; Kwon et al., 1995;
Jordan, 1996; Kwon and Gurney, 1996). Because evidence sug-
gests that neuronal growth factors both influence synaptic activity
and in turn can be regulated by neural activity, these factors may
be mediators of activity-dependent synaptic plasticity (Ghosh et
al., 1994; Li et al., 1998; Berninger et al., 1999; Kang and Schu-
man, 2000) (for review, see Snider and Lichtman, 1996; Schuman,
1999).
The actions of growth factors on synaptic connections could be
indirect, because of effects on the degree of axon branching or on
the number of axons (for example by preventing neuronal cell
death). Alternatively, growth factors could directly influence syn-
apse formation, maintenance, competition, or some combination.
Deciding between these alternatives is complicated in the CNS,
where both presynaptic and postsynaptic components may ex-
press receptors for the same trophic factor (McAllister et al.,
1995, 1997).
Developing neuromuscular junctions undergo a stereotypical
alteration in synaptic connections known as synapse elimination
(Brown et al., 1976; Balice-Gordon et al., 1993), which seems
analogous to central rearrangements, but is far easier to analyze.
At the NMJ, transgenic overexpression of glial cell line-derived
neurotrophic factor (GDNF), the most potent trophic factor yet
described for motor neurons, leads to a dramatic increase in the
number of motor axons innervating muscle fibers at a time when
axons are ordinarily being eliminated (Nguyen et al., 1998). This
effect suggested that GDNF might be an important regulator of
synapse elimination. However, the interpretation of the mode of
action of GDNF is ambiguous because transgenic GDNF expres-
sion began before the period of programmed cell death [approx-
imately embryonic day 9.5 (E9.5)] (Cheng et al., 1992), allowing
GDNF to alter the number or behavior of motor axons while they
are in the process of growing to targets.
Because the effects of transgenic GDNF on NMJ innervation
are so dramatic and because an increased understanding of this
effect may shed light on the regulation of synapses by growth
factors, we thought it important to investigate the mechanism by
which GDNF alters NMJ innervation. A pharmacological ap-
proach might provide useful information because exogenous ad-
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ministration can be used to control the amount, onset, and dura-
tion of GDNF exposure. We thus could ask if higher levels of
circulating GDNF could maintain multiple innervation at the
NMJ indefinitely, which did not occur in the transgenic animals
expressing lower and uncontrolled levels of GDNF (Nguyen et
al., 1998). We also could easily test whether GDNF-related mol-
ecules such as neurturin (NTN) (Kotzbauer et al., 1996; Klein et
al., 1997; Milbrandt et al., 1998) had similar effects.
Here, we report that early postnatal subcutaneous injection of
GDNF (but not NTN) induces sustained multiple innervation,
but GDNF injections begun after the first postnatal week were
without effect. Moreover, if GDNF administration is begun early,
and continued into adulthood, multiple innervation persists. In
these adult animals, there is evidence of ongoing synapse elimi-
nation despite the retention of multiple innervation. Morpholog-
ical analysis of single labeled motor axons reveals that the hyper-
innervation is quantitatively explained by an increase in motor
unit size, not motor neuron number. Our results demonstrate that
GDNF promotes axon branching and synapse formation at NMJs
in postnatal life and, if applied during a developmentally re-
stricted time, GDNF may induce a continuous state of synaptic
remodeling.
MATERIALS AND METHODS
Protocol for injection of factors. Human recombinant (hr) GDNF was
obtained from Amgen (Thousand Oaks, CA), and rat recombinant NTN
was kindly supplied by G. Johnson (Washington University, St. Louis,
MO). Both growth factors were diluted to a working concentration of 2.5
mg/ml in sterile PBS, pH 7.4. GDNF was stored at 70°C until dilution,
after which it was kept for a maximum of 4 d at 4°C. Before injection, the
skin was sterilized by wiping with 70% alcohol. Subcutaneous injections
were done twice daily with a 10 l Hamilton syringe at a dose of 0.5
g/gm or 2.0 g/gm in the back of the neck beginning on either postnatal
day 0 (P0) or P10. The volume of injection ranged from 0.2 to 20 l.
Injections continued until P8, P23, P30, or P40. Control injections were
done identically to experimental injections, using PBS alone.
Animals. Timed pregnant CF-1 strain females were obtained from
Charles River (Wilmington, MA). Thy1-YFP transgenic mice were pro-
duced at Washington University (St. Louis, MO) (Feng et al., 2000). The
day of birth was considered postnatal day 0. On the day of the terminal
experiment, mice were deeply anesthetized with sodium pentobarbital
(0.65 mg/gm body weight) and perfused transcardially with heparin in
PBS, pH 7.4, followed by 2% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4. Sternomastoid and spinotrapezius muscles were carefully
dissected and post-fixed in paraformaldehyde for 2 hr. The connective
tissue surrounding the muscle was then removed, and the tissue was
incubated overnight in PBS with 0.1 M glycine.
Tissue staining. Sternomastoid muscles from CF1 and spinotrapezius
muscles from thy1-YFP mice were incubated for 30 min at room temper-
ature in 5 g/ml tetramethylrhodamine-conjugated -bungarotoxin (Mo-
lecular Probes, Eugene, OR) that was diluted in 1% bovine serum
albumin (BSA) in sterile lactated Ringer’s solution. The muscles were
then rinsed 3 hr in PBS. Thy1-YFP spinotrapezius muscles were then
mounted on glass slides in Vectashield mounting medium (Vector Lab-
oratories, Burlingame, CA) for imaging. CF1 sternomastoid muscles
were immunostained by blocking in 4% BSA and 0.5% Triton X-100 in
PBS overnight at 4°C. The next day, muscles were incubated in mouse
anti-phosphoneurofilament antibody SMI312 (Sternberger Monoclonals,
Lutherville, MD) diluted 1:500 and the mouse synaptic vesicle antibody
SV2 (Developmental Studies Hybridoma Bank, The University of Iowa,
Department of Biological Sciences, IA City, IA) diluted 1:10 in blocking
solution. After washing 5 hr in 1.0% Triton X-100 in PBS, the tissue was
incubated overnight in a 1:200 dilution of goat anti-mouse antibody
conjugated to the fluorescent label Alexa 488 (Molecular Probes). Im-
munostained muscles were also mounted in Vectashield on glass slides.
Muscles to be stained for Ret or GFR-1 were dissected from unfixed
animals, embedded in OCT (Tissue-Tek, Miles Inc., Elkhart, IN), and
quick frozen with liquid nitrogen. Twenty micrometer sections through
the endplate band were cut on a cryostat and thaw-mounted on glass
slides for immunohistochemistry. Rabbit anti-Ret (R & D Systems,
Minneapolis, MN) and goat anti-GFR-1 (KMI Diagnostics, Minneap-
olis, MN) were diluted 1:200 and 1:150, respectively, in blocking solution
(see above). Tissue was incubated overnight at 4°C. After washing in
PBS, sections were incubated 3 hr with either anti-rabbit or anti-goat
secondary antibodies conjugated to Alexa 488 (Molecular Probes). After
rinsing, slides were coverslipped with Vectashield (Vector Laboratories)
and imaged.
Data collection. For each time period and each dose of growth factor,
a minimum of two animals (four sternomastoid muscles) was examined.
An approximately even distribution of male and female pups was used.
When muscles from different animals in the same experimental condition
were used, we first determined whether there were statistically significant
differences within the group before combining data. In no case did
muscles within an experimental group differ significantly from each
other; therefore, “n ” in the text refers to the number of NMJs counted.
Approximately 50 junctions per muscle were counted to determine the
percent multiple innervation and the mean number of axons per receptor
plaque. Data are expressed as the mean number of axons per muscle
fiber  the SD, unless otherwise noted.
A Nikon Optiphot microscope with a 50 water immersion lens was
used to examine and count the number of axons per junction. Thy1-YFP
single motor units (and Ret/GFR-1-labeled tissue sections) were im-
aged on an Olympus Optical (Tokyo, Japan) (BX50WI) microscope
using a laser-scanning confocal microscope (model 1024; Bio-Rad, Her-
cules, CA). Images were obtained with a 40 (1.35 NA) oil objective.
Z-stacks were flattened with Confocal Assistant, and montages of col-
lapsed image stacks were assembled using Adobe Photoshop.
RESULTS
Initially, we tested daily subcutaneous doses of GDNF in new-
born pups at 2.5 g/gm and higher, but the animals rarely sur-
vived the first postnatal week. Therefore, to examine the effects of
GDNF on neuromuscular junctions in postnatal life, we injected
either 2.0 or 0.5 g/gm GDNF twice daily into CF1 pups for
periods (8–40 d) beginning at various time points after birth.
Subcutaneous injection of either 2.0 or 0.5 g/gm GDNF begin-
ning at birth rapidly produced weight loss, and several days later
tail kinks and tremors were evident (Fig. 1). These same charac-
teristics were observed at birth in transgenic animals expressing
Figure 1. GDNF injection results in tail kinks, weight loss, and tremor.
Three postnatal day 10 CF1 littermate pups are shown. Each pup was
injected with PBS (lef t), 0.5 g/gm GDNF (middle), or 2.0 g/gm GDNF
(right) beginning at birth. There is a dose-dependent increase in tremor,
as noted in the insets (time lapse: 1 sec exposure). A, PBS; B, 0.5 g/gm
GDNF; C, 2.0 g/gm GDNF.
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GDNF in muscles (Nguyen et al., 1998). Animals injected twice
daily with 2.0 g/gm GDNF for the first 7 d after birth weighed
an average of 21% less than their PBS-injected littermate con-
trols, and pups injected with 0.5 g/gm for the same time period
weighed an average of 2% less than controls. When the high dose
GDNF injections were continued into later life (P0–P40), ani-
mals were 17% smaller than control P40 mice. The magnitude of
tremor was higher and persisted longer in the mice injected with
the higher dose of GDNF. Injection of the related factor, NTN,
at doses of 3.0 or 0.5 g/gm twice daily produced no external
phenotypic changes.
Effects of GDNF and NTN on neuromuscular
innervation at P8
In pups injected twice daily with saline from P0 through P8, 37%
of the sternomastoid muscle fibers were multiply innervated at P8
(mean  1.4  0.5 axons per NMJ; n  411). This number was
significantly higher in pups injected from birth with 2.0 g/gm
GDNF; 99% of junctions at P8 were multiply innervated (mean 
3.3  1.1; n  199; p  0.000001; Student’s t test) (Table 1, Fig.
2B). However, after treatment many of the axons were of unusu-
ally small caliber, and when adjacent to other axons, difficult to
resolve, suggesting that we may have underestimated their num-
ber. In animals treated with the low, 0.5 g/gm, GDNF dose, the
incidence of multiple innervation (93%) and average number of
axons per NMJ (mean  2.9  1.0; n  318) was also significantly
greater than controls ( p  0.000001; Student’s t test). The effect
of the low dose of GDNF was however, significantly less than the
effects of the high dose of GDNF ( p  0.0002; Student’s t test).
We surveyed several other muscles in the GDNF-treated animals,
including two in the hindlimb (gastrocnemius and soleus), and
found similar effects on multiple innervation.
Injection of the related factor neurturin at 0.5 g/gm had no
effect on the number of axons innervating muscle fibers, and
injection of 3.0 g/gm produced no significant increase in NMJ
innervation at P8 (1.5  0.5; n  122) (Table 1). These results
show that augmenting GDNF levels, but not NTN, in postnatal
animals had comparable effects to transgenic GDNF expression
beginning in embryonic life.
Interestingly, the number of axons per junction in P8 pups after
GDNF injection of 2.0 or 0.5 g/gm is 2.1 axons per junction
Table 1. Number of axons per muscle fiber at various ages
P0 P8 P23 P30 P40
PBS 2.1a 1.4  0.5 1.0  0.05 1.0  0.1 1.0  0
GDNF (0.5 g/gm) “ 2.9  1.0 1.5  0.6 1.4  0.6 ND
GDNF (2.0 g/gm) “ 3.3  1.1 2.1  1.0 1.7  0.7 1.8  0.8
NTN (0.5 g/gm) “ 1.4  0.5 ND ND ND
NTN (3.0 g/gm) “ 1.5  0.5 ND ND ND
aEstimated from Balice-Gordon and Lichtman (1993).
ND, Not determined.
Figure 2. Postnatal GDNF injection produces hy-
perinnervation of neuromuscular junctions in sterno-
mastoid muscle. A, B, Confocal reconstructions of
part of the endplate band from a P8 mouse after
twice-daily PBS (A) or 2.0 g/gm GDNF (B) injec-
tions beginning at birth. C, D, Higher magnification
confocal reconstructions of a single neuromuscular
junction in control (C) and GDNF-exposed (D) ster-
nomastoid muscles at P8. Four different axons inner-
vate the junction in the GDNF-exposed mouse (D,
arrows), whereas only one axon innervates the control
junction (C). Note that in the GDNF-exposed junc-
tion (D), axon number 4 is relatively small compared
with the other three inputs. Axons are labeled with
anti-neurofilament antibodies ( green), and postsynap-
tic acetylcholine receptors are labeled with tetra-
methylrhodamine--bungarotoxin (red).
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estimated from electrophysiological studies of wild-type sterno-
mastoid muscle at P0 (Balice-Gordon and Lichtman, 1993), sug-
gesting that GDNF is able to induce presynaptic branching.
Presynaptic branching
To directly assess the effect of GDNF on motor neuron morphol-
ogy, we examined the entire branching pattern of single motor
units in P8 muscles after twice-daily injections of 2.0 g/gm
GDNF beginning at birth. To analyze individual motor units, we
used a line of transgenic mice (thy1-YFP) that expresses yellow
fluorescent protein (YFP) in only a few motor neurons per motor
pool during postnatal life (Feng et al., 2000) (our unpublished
observations). For this study, we chose the spinotrapezius muscle
because it is a thin muscle (unlike the sternomastoid, which was
used previously) that is ideal for imaging the entire arbor of
individual motor axons. In control muscles, each motor axon
enters the muscle rostrally and sends off branches as it courses
caudally (Fig. 3A). At P8, labeled motor units in control animals
contact an average of 55  15 (n  5) muscle fibers. After GDNF
injection, the size of single motor units more than doubled, with
each axon contacting an average of 112  18 muscle fibers at P8
(n  2; p  0.008) (Fig. 3B,C). Thus, GDNF exposure in post-
natal life leads to a large-scale increase in the size of motor units.
To determine if the degree of expansion of GDNF-injected
motor units was consistent with the degree of multiple innerva-
tion in spinotrapezius muscle, we analyzed individual junctions
from single motor units in GDNF-injected and control animals.
The YFP-labeled axon occupies all the acetylcholine receptors in
junctions that are singly innervated. In contrast, junctions that
have not completed synapse elimination are only partially occu-
pied by the labeled axon (our unpublished observations). Thus, by
analyzing the degree of receptor occupation, it is possible to
determine the percentage of endplates that are still multiply
innervated in a motor unit. In the control muscles at P8, 75% of
spinotrapezius neuromuscular junctions had completed synapse
elimination and were singly innervated. In the GDNF-treated
muscles, 15% of the NMJs were singly innervated ( p  0.001; z
test). If the remaining 85% of multiply innervated junctions had
just two axons innervating them, there would be an average of
1.75 axons per junction. This number is consistent with the
approximately twofold increase in the size of motor units.
We also analyzed the particular branching patterns of individ-
ual motor axons after GDNF injection (Fig. 4). To do this, we
began by counting the number of axonal branch points between
the cell body and each NMJ. In control animals, each neuromus-
cular contact in a motor unit was an average of 11.12 branch
points from the cell body. Each NMJ in GDNF-injected animals
was an average of 11.48 branch points from the cell body. Fur-
thermore, the most distal NMJ in controls was found 26 branch
points from the cell body (mean  19), whereas the most distal
NMJs in GDNF motor units were found up to 22 branch points
from the cell body (mean  19). Thus, GDNF exposure affects
the branching of motor units in such a way that uniform expansion
of the motor unit is produced.
One way this uniform effect could occur is if GDNF caused
terminal axon branches (those branches directly contacting end-
plates) to bifurcate. In contrast to controls, terminal branches in
the GDNF-exposed animals often innervated multiple neighbor-
ing muscle fibers. For example, within a single 60 m2 field of
view from a GDNF-treated P8 mouse, in which at least one
labeled terminal branch was present, two or three NMJs inner-
vated by the same labeled motor axon could be visualized 20 or
12% of the time, respectively. In PBS-injected motor units, two
NMJs were infrequently observed in a single field of view (8%),
and three were never observed. The increase in the number of
double- and triple-labeled neuromuscular junctions within a sin-
gle field of view after GDNF exposure was significant ( p  0.001
in both instances). To control for the possibility that more labeled
endplates were visible in a single field of view because the muscle
fibers were smaller after GDNF injection, we counted the total
number of receptor plaques in each field of view. Per field, the
total number of endplates was not significantly different between
GDNF and the control (1.7 vs 1.8, respectively). Taken together,
these data suggest that the increase in motor unit size after
GDNF injection occurs by increased terminal branching.
Synaptic maintenance
For the reasons described above, the larger motor units seen in
GDNF-treated mice seem to be attributable at least in part to an
induction of axonal branching. However, it is also plausible that
GDNF alters synapse survival and thereby allows more of the
initially formed branches to be maintained during the period of
synapse elimination. One objective of this study was therefore to
determine whether sufficiently high concentrations of GDNF
could maintain multiple innervation. We injected GDNF at 2.0 or
0.5 g/gm from P0 until P23, P30, or P40. The results are shown
in Table 1.
Despite the twice-daily dose of injected GDNF, the number of
axons per fiber decreased as the animal matured. Furthermore,
even at postnatal day 8, the first time period examined, some
branches of a motor unit had completed synapse elimination (Fig.
4). These results suggest that GDNF by itself is unable to main-
tain the high level of multiple innervation observed during the
first postnatal week, and therefore GDNF cannot prevent synapse
elimination from occurring. However, when compared with con-
trol animals, significantly more multiple innervation was evident
in mice injected with GDNF (2.0 g/gm) through P40 (1.8  0.8;
n  184) compared with uninjected mice (1.0  0; n  81; p 
0.000001; Student’s t test). In the presence of a continual supply
of GDNF, a plateau was reached at P30, because there was no
significant difference between the number of axons per fiber at
P30 (1.7  0.7; n  245) and P40 (1.8  0.8; n  184; p  0.09;
Student’s t test). Despite no change in the number of multiply
innervated fibers from P30 to P40, chronic GDNF exposure
starting at birth was still affecting neuromuscular junction inner-
vation at these late ages because discontinuation of GDNF ad-
ministration at P30 caused the number of multiply innervated
neuromuscular junctions to drop to an average of 1.4  0.8 (n 
87) by the age of P40. This result is interesting because GDNF
treatments begun after P10 had no effects on neuromuscular
innervation at any age (see below).
In chronically treated mice, multiple innervation of junctions
always decreased after withdrawal of GDNF (Fig. 5). For exam-
ple, stopping GDNF injections at P10 resulted in a 30% decrease
in the number of axons per NMJ at P23 compared with continual
injection from P0 to P23. Moreover, this decrease was statistically
significant ( p  0.000001; Student’s t test). Discontinuing GDNF
injection at P10 and examining junctions at P30 also produced a
significant (30%) decrease in the number of axons per junction
compared with continual injection ( p  0.000001; Student’s t
test). Finally, when GDNF injection is discontinued at P10 and
the number of axons per junction counted at P40, the level of
multiple innervation begins to approach that of control, PBS-
injected muscles (i.e., 1.0  0). Specifically, at P40, 38% fewer
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Figure 3. Completely reconstructed motor units in postnatal day 8 spinotrapezius muscle show a twofold increase in branching after GDNF injection.
Montages of confocal reconstructions from postnatal day 8 transgenic mice (thy1-YFP) reveal single motor axons that express yellow fluorescent protein.
Axons appear green, and acetylcholine receptors are labeled with rhodamine--bungarotoxin (red). The expanse of each motor unit is shown in the small
diagram to the right of each photomontage. The pink patches in the diagrams are areas where neuromuscular junctions are clustered. A, Control motor
units, such as the one shown, are relatively simple. B, C, In contrast, GDNF-exposed motor units (2.0 g/gm GDNF) are more complicated. The control
motor unit in A formed 57 neuromuscular contacts. The GDNF motor unit in B formed 99 neuromuscular contacts, and the motor unit in C formed 124.
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axons innervate NMJs when GDNF is stopped at P10 than when
GDNF is not stopped until examination ( p  0.000001; Student’s
t test). These data indicate that a continual supply of GDNF is
required to exert long-term effects on neuromuscular innervation.
Continuous branch remodeling is induced by GDNF
To better understand how GDNF caused persistent multiple
innervation, we examined confocal images of labeled sternomas-
toid and spinotrapezius preparations from P8 to P40 for the
presence of retraction bulbs (very thin axons with bulbous end-
ings) and sprouts, in mice treated with GDNF from birth. As
expected, given the decrease in the number of axons per junction
after the first postnatal week, many retraction bulbs were ob-
served in GDNF-treated animals. Interestingly, numerous retrac-
tion bulbs were present at both P30 and P40 (Fig. 6B), despite the
fact that the number of axons per fiber did not decrease during
this period, implying that axons may have been both retracting
and re-growing. Consistent with this view, terminal and nodal
sprouts were present throughout postnatal life after GDNF ad-
ministration (Fig. 6C–H). These results suggest that a dynamic
state of active axon growth and retraction may be occurring in the
presence of GDNF.
While examining the innervation of junctions in GDNF in-
jected pups, we also noted that many of the receptor sites ap-
peared morphologically abnormal compared with littermate con-
trols. In neonatal pups 2 weeks of age, acetylcholine receptors
(AChRs) tend to be clustered in smooth, oval plaques. As the
animal matures, these plaques increase in size and become per-
forated, transforming the plaque into a “pretzel-like” morphology
(Marques et al., 2000). At P8, AChR plaques from GDNF-
treated mice (2.0 g/gm) were significantly larger in both area
(30%; p  0.001) and length (20%; p  0.001) (Fig. 7A). This
increase in size occurred despite the fact that the mice are smaller
Figure 4. Branching diagrams for two
motor units after GDNF injection show
expansion of the motor unit around the
cell body (A is the motor unit shown in
Fig. 3B, and B is the motor unit shown in
Fig. 3C). The number of branch points
between each neuromuscular junction and
the cell body (MN ) is shown to the lef t of
each diagram. The junctions are color-
coded so that singly innervated NMJs
(i.e., those that have completed synapse
elimination) are red, and junctions that
are partially occupied, and therefore mul-
tiply innervated, are green. Gray circles
indicate junctions that were oriented
such that we could not determine
whether or not they had completed syn-
apse elimination.
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at P8 than control (see above). Interestingly, by postnatal day 30,
the effect had reversed. After injection of 2.0 g/gm GDNF,
AChR clusters were now significantly smaller and much simpler
than the age-matched controls. In the 2.0 g/gm-injected animals
at P30, receptor plaques were 23% smaller in area ( p  0.001)
and 20% smaller in length ( p  0.001) than the control (Fig.
7B–D). In addition, the number of AChR-containing branches
within a neuromuscular junction was fourfold lower in the
GDNF-treated animals (mean 3.2  1.6 branches) than in con-
trols (mean 11.8  2.0 branches) at P30. In the low-dose animals,
the receptors were 12% smaller in area and 19% smaller in
length. Thus, despite the ability of GDNF to induce hyperinner-
vation and larger postsynaptic AChR sites in early postnatal life,
prolonged synaptic remodeling seemed to ultimately have dele-
terious effects on the AChR areas. Perhaps repeated volleys of
synaptic withdrawal, induced by GDNF, caused an exaggeration
of the naturally occurring AChR loss seen during the period of
naturally occurring synapse elimination in early postnatal life (for
review, see Lichtman and Colman, 2000).
Developmentally restricted responses to GDNF
To determine whether motor neurons were equally responsive to
GDNF at all ages, GDNF was injected twice daily starting at P10
rather than at P0, and the number of axons per NMJ was exam-
ined at P23. Surprisingly, injections begun at P10 resulted in no
polyneuronal innervation (1.0  0; n  205), and in fact the
NMJs were indistinguishable from those in animals injected with
PBS alone. Moreover, tail kinks and tremor were not observed
when injections were begun at P10. The inability of motor neu-
rons to respond to GDNF injection after P10 thus marks the end
of a critical period of susceptibility in motor neuron development
that approximates the end of naturally occurring synapse elimi-
nation. This implies that continual exposure to GDNF from birth
prevents motor axons from maturing appropriately, and therefore
permits axons to maintain their responsiveness to GDNF.
One possible explanation for the decreased ability of GDNF to
induce branching after postnatal day 10 is that axonal responsive-
ness to GDNF diminishes, perhaps because GDNF receptor
components are no longer present on axons after the first post-
natal week. Substantial evidence exists that motor neuron cell
bodies continue to express both the Ret and GFR-1 components
of the GDNF receptor into adulthood (Golden et al., 1998).
Nonetheless, it is unknown whether these receptors are also
present on axons in adulthood. To test the possibility that GDNF
receptors are excluded from intramuscular axon branches after
the first postnatal week, we immunostained P2, P14, and adult
sternomastoid muscles for both Ret and GFR-1. Strong Ret
label was detected at the neuromuscular junctions at all ages
studied. The labeling appeared presynaptic, although terminal
Schwann cell staining could not be excluded. Weak labeling of the
intramuscular nerves was also observed at all ages. The result was
similar for GFR-1; labeling was detected at the neuromuscular
junction at all ages (although it was substantially weaker than the
Ret staining). Strong GFR-1 staining was found in the intra-
muscular nerves at the same three ages. These results suggest that
the components for functional GDNF receptors persist in motor
axons as the animals mature, and therefore the lack of respon-
siveness of motor neurons to exogenously applied GDNF after
postnatal day 10 is unlikely to be explained by receptor
redistribution.
DISCUSSION
The GDNF family of polypeptide growth factors has multiple
regulatory roles during neural development in many ways analo-
gous to those of the neurotrophins (for review, see Baloh et al.,
2000). GDNF is the most potent neuronal growth factor de-
scribed for developing motor neurons both in vitro (Henderson et
al., 1994) and in vivo (Li et al., 1995; Oppenheim et al., 1995; Yan
et al., 1995). The biological action of GDNF is mediated by a
two-component receptor complex that consists of a ligand binding
glycosylphosphatidylinositol-linked cell surface protein, GFR-1
(Jing et al., 1996; Treanor et al., 1996), and a receptor tyrosine
kinase encoded by the c-Ret proto-oncogene (Ret; Durbec et al.,
1996; Trupp et al., 1996). Consistent with its trophic effects on
motor neurons, GDNF is expressed in developing nerves and
skeletal muscle at the time axons project to, and branch in, muscle
fibers (Trupp et al., 1995; Nosrat et al., 1996). Additionally, motor
neurons express the two-component GDNF receptor complex
Figure 5. Continual GDNF injection is required to main-
tain multiple innervation. Graph showing the effects of dis-
continuing GDNF injection at postnatal day 10 (hatched
bars) compared with continual injection (black bars). We
injected 2.0 g/gm GDNF in all animals beginning at birth.
When GDNF is discontinued at postnatal day 10 (hatched
bars), synapse elimination rapidly proceeds, and by postnatal
day 40 ( far right, hatched bar) the number of axons per
junction has almost reached control levels (1.0 axons/NMJ).
In animals receiving GDNF injection from P0 to P10, n 
203, 199, and 150 at P23, P30, and P40, respectively. In
animals receiving GDNF injection from P0 until examina-
tion, n  309, 244, and 183 at P23, P30, and P40, respectively.
Asterisks indicate statistically significant differences (see Ma-
terials and Methods). Error bars indicate mean  SE.
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(Pachnis et al., 1993; Tsuzuki et al., 1995; Naveilhan et al., 1997;
Trupp et al., 1997), including the ligand-binding component
GFR-1 (Jing et al., 1996; Treanor et al., 1996) and the signal-
transducing component Ret tyrosine kinase (Durbec et al., 1996;
Trupp et al., 1996). The expression of GDNF and its receptors
strongly suggests that GDNF is an important target-derived fac-
tor for spinal neuron survival, differentiation, and/or synaptic
remodeling.
In this study, we have shown that augmentation of GDNF
levels by subcutaneous injection in the postnatal period results in
hyperinnervation of neuromuscular junctions. This effect is quite
similar to that obtained by target mediated delivery of GDNF
(Nguyen et al., 1998), indicating that a localized postsynaptic
target supply of growth factor is not required for its effects on
synapses. We have found that the hyperinnervation is entirely
explained by an increase in the overall size of single motor units,
such that they are twice as large as control motor units at P8.
Therefore, these results show that in addition to the effects of
GDNF on motor neuron survival in embryonic life (Oppenheim
et al., 2000), GDNF also has potent effects on axonal arbors
in postnatal life. Continued administration of GDNF is required
to maintain the multiple innervation at later ages. Nevertheless,
synapse elimination still proceeds to some degree even in
the presence of high levels of GDNF, suggesting that GDNF
likely plays a minimal role in maintaining synapses. Moreover,
analysis of morphological changes in both the axon and the
receptor area suggests that a dynamic remodeling of neuromus-
cular junctions occurs in the presence of exogenous GDNF.
Finally, we have shown that this effect of GDNF is developmen-
tally restricted, because even very high doses of exogenous
GDNF do not produce multiple innervation if administration is
begun after P10.
GDNF injections also altered the animal’s external appear-
ance. When GDNF was begun in the first postnatal week, tail
kinks and tremor were observed but not when injections were
begun later. These outward signs correlated with the morpholog-
ical changes in axon branching (i.e., higher doses of GDNF
produced more multiple innervation at P8, and also a greater
degree of tremor). It is possible that both the tremor and the tail
kinks are attributable to the larger size of motor units produced
by GDNF. Each motor unit, because of its increased size, would
cause significantly more noticeable muscle twitching when the
motor axon was stimulated, leading to a tremor. The tail kinks
may derive from unbalanced muscle tone because of a greater
Figure 6. GDNF induces a dynamic state of axonal branching. A, Confocal reconstruction of a neuromuscular junction from control sternomastoid
muscle at P40 shows that the junctions are large, singly innervated, and have a complicated pattern of receptor branches that accurately mirrors the
branching pattern of the overlying terminal axon, which possesses no sprouts. B, C, In contrast, after 40 d of continual exposure to 2.0 g/gm GDNF,
junctions are often multiply innervated (C), smaller in area, and somewhat less complex than controls. Furthermore, many thin axons, terminating in
bulbs, were evident (arrow, B). These structures are identical in appearance to “retraction bulbs” seen during naturally occurring synapse elimination
in the first 2 postnatal weeks (Bernstein and Lichtman, 1999). Additionally, axons that ended in structures that resembled growth cones were observed
in GDNF-exposed muscles (C, and enlargement shown in D). E, F, Also observed at P40 in GDNF-treated muscles were terminal sprouts that either
connected nearby junctions (E) or exited neuromuscular junctions but ended blindly (F). G, H, Such sprouting was also seen at earlier ages. Shown here
(G) is a blindly ending sprout off a YFP-labeled axon from a P8 spinotrapezius muscle in a mouse treated with GDNF since birth and a neuromuscular
junction with three terminal sprouts (H ) from the same animal, suggesting that throughout the duration of GDNF exposure axons were sending out new
processes in the muscle. Scale bar shown in A is the same for B and C. In A–F, axons are labeled with anti-neurofilament antibodies ( green), and
postsynaptic acetylcholine receptors are labeled with rhodamine--bungarotoxin (red).
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number of muscle fibers activated by some motor neurons inner-
vating tail musculature.
GDNF and synaptic rearrangements
In previous work, a significant effect of transgenically supplied
GDNF on the number axons innervating the NMJ was shown
(Nguyen et al., 1998). In Myo-GDNF mice the transition from
multiple innervation to single innervation was delayed by 2
weeks. One interpretation of this work is that neuronal growth
factors somehow stabilize synapses and prevent the rearrange-
ments that would ordinarily occur. The present results suggest
however that the effect is predominantly by induction of axonal
branches.
Two quantitative and three morphological lines of evidence
support this view. First, the degree of multiple innervation in-
duced by GDNF at P8 is greater than the degree of multiple
innervation at P0, as determined by physiological methods
(Balice-Gordon and Lichtman, 1993). Furthermore, because of
the small caliber and tight fasciculation of axons at P8, we un-
doubtedly underestimated the degree of multiple innervation
induced by GDNF. Second, even in the face of high levels of
circulating GDNF, the number of axons per receptor plaque
declined almost 50% as the animal matured (from 3.3 at P8 to 1.8
at P40). These data suggest that GDNF is unable to maintain
synaptic connections.
There is also a significant amount of morphological evidence
that synapse elimination is continuing in the presence of GDNF.
First, endplates were markedly smaller than normal at P30, sug-
gesting that synaptic remodeling was ongoing, because synapse
loss has been associated with AChR loss (Lichtman and Colman,
2000). Second, in 1-month-old animals exposed to GDNF from
birth, retraction bulbs, structures that are specifically associated
with synaptic withdrawal during the period of normal synapse
elimination (Bernstein and Lichtman, 1999), were frequently en-
countered in the endplate band. At normal adult NMJs there is
no evidence of synaptic rearrangement. Third, sprouts, and other
larger caliber axons not contacting endplates, were sometimes
found in mature muscles after GDNF exposure. The combination
of both presynaptic and postsynaptic changes suggests that the
effect of GDNF is to induce a continual state of sprouting and
elimination that results in a situation in which some fraction of
the endplates are multiply innervated at every observation.
Specificity and temporal responses to GDNF
The specificity of morphological changes for GDNF is an inter-
esting feature of our results. Motor neurons express receptors for
Figure 7. Acetylcholine receptor
plaques are abnormal in GDNF-
injected animals. A, Average area
(lef t) or length (right) of acetylcholine
receptor plaques at P8 after continual
exposure to either GDNF (white bars)
or PBS (black bars). The small inset in
A, lef t, shows the size frequency histo-
gram of acetylcholine receptor area in
P8 GDNF-exposed animals (white
bars) compared with control (black
bars). At P8, receptor plaques are
larger ( p  0.001) and longer ( p 
0.001) after GDNF injection than in
control muscles. B, Average area (lef t)
or length (right) of acetylcholine re-
ceptor plaques at P30 after continual
exposure to either GDNF (white bars)
or PBS (black bars). At P30, AChR
plaques in GDNF-injected sternomas-
toid muscles are now significantly
smaller than controls in area ( p 
0.001) and length ( p  0.001) and are
also less complex (see below). C, D,
Photomicrographs of P30 receptor
plaques. C, AChRs in control junc-
tions show many small perforations
and bifurcations. D, High doses (2.0
g/gm) of GDNF decrease the com-
plexity and size of the receptor area.
One of every six junctions (n  30)
that were photographed is shown from
least complex to most complex (lef t to
right). Error bars indicate mean  SE.
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multiple neurotrophins, GDNF family, cytokine, and other
growth factors (Henderson et al., 1998). However, our results
here show that subcutaneous injection of the GDNF family mem-
ber neurturin at 3.0 g/gm does not produce multiple innerva-
tion, and it has been previously shown that transgenically over-
supplied NT-3 and NT-4 were also ineffective (Nguyen et al.,
1998). Furthermore, the use of adenoviruses to deliver truncated
trk receptors to scavenge neurotrophins has shown primary ef-
fects on muscle fibers and Schwann cells, rather than direct effects
on motor axons (Gonzalez et al., 1999). In vitro, GDNF has
shown more robust growth-promoting effects on motor axons
than any other factor (Henderson et al., 1994; Ho et al., 2000). At
the moment there is no clear-cut explanation for the specificity of
the morphological responses to GDNF. These results suggest that
that Ret (and not the trks) activates signal transduction mediators
specifically linked to morphological responses in motor neurons.
One of the effects of the neurotrophins at the neuromuscular
junction may be to regulate assembly of postsynaptic receptors
(Yan et al., 1995; Gonzalez et al., 1999).
Whereas GDNF induced extensive growth of axons, these
increased branches were constrained to the endplate band. A
possible explanation of this lack of widespread exuberant growth
is that the motor axon branches may be restricted to grow along
Schwann cells and that the growth effect does not encourage
axons to escape from their glial sheaths (Son and Thompson,
1995a,b). These morphological responses raise the issue of the
role of GDNF in regeneration. After axotomy there is a dramatic
upregulation of GDNF by Schwann cells and muscle (Trupp et
al., 1995, 1997; Naveilhan et al., 1997). Furthermore, injection of
the GDNF gene in individual muscle fibers produces consider-
able motor axon growth and branching (Bernstein et al., 1998; our
unpublished observations). These data are consistent with the
idea that GDNF promotes a more rapid regenerative response
(Naveilhan et al., 1997). However, our results raise the possibility
that GDNF regulation of regeneration is more related to terminal
branching than to extension of axons down a damaged nerve.
The branching pattern of motor axons observed in GDNF-
treated mice suggested that the effect of GDNF was primarily on
terminal branches. If GDNF had caused motor axons to undergo
a greater number of proximal bifurcations, then the number of
branch points between each endplate and the cell body would
have been increased. However, the average number of branch
points remained the same (although the total number of NMJs
contacted by the motor axon increased twofold). Thus, the added
neuromuscular junctions must have come from terminal branches.
The temporal restriction of GDNF effects is also of consider-
able interest. We saw no effect on motor axon branching if GDNF
was first administered after postnatal day 10. Adult motor neu-
rons continue to express Ret and should in theory respond to
GDNF (Golden et al., 1998). A spatial exclusion of Ret from axon
terminal regions is a plausible explanation for the loss of axon
responsiveness. However, we have found that there is no detect-
able difference in the expression of GDNF receptors in the
intramuscular branches of motor axons between P2 and adult-
hood. Presumably the difference in GDNF responsiveness with
age is downstream of the receptor per se. Thus, the change in
GDNF reactivity may reflect a broader downregulation of axon
growth potential as neurons mature. In this regard it should be
noted that sensory neurons when initially plated in culture do not
respond with axon elongation unless they have been previously
axotomized (Smith and Skene, 1997). In other work we have
shown that axotomy restores the ability of motor axons to respond
with growth and branching to GDNF (Bernstein et al., 1998; our
unpublished observations). This may explain why GDNF has
persistent effects after P8 when started early: axons may remain in
a growth state in its presence and thus remain sensitive to the
factor.
Conclusions
Here, we sought to maintain high levels of GDNF through phar-
macological means to test the premise that competition for a
growth factor in limited supply would be inhibited by excess
growth factor, and therefore a powerful motor neuron growth
factor might prevent synapse elimination. However, our results
suggest that the role of GDNF is in growth and branching, and
therefore synapse loss may more likely be regulated by other
kinds of signals such as those that maintain and disrupt the
adhesion of the nerve to the postsynaptic site. Nonetheless,
GDNF appears to have extremely potent effects on axonal
branching and synapse formation in early postnatal life, and these
effects can persist into adult life when GDNF exposure is
maintained.
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